Medication before surgery for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether giving rezvilutamide before surgery can help treat high-risk prostate cancer. It may improve surgery outcomes and reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer that is grade group 2 or higher (Gleason score 7 or above).
- Your cancer is high-risk or locally advanced, meaning it has not spread to distant organs, but may be growing outside the prostate or into nearby lymph nodes.
- Your doctors believe that surgery can completely or almost completely remove the cancer.
- Your blood counts, liver, and kidney function are within acceptable levels.
- You have not had radiation, cryotherapy, or chemotherapy for prostate cancer in the past.
- You have not had other cancers in the last 5 years (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, Rezvilutamide, for men with prostate cancer that was removed by surgery but has features that make it more likely to come back. It's an alternative for those who don't want or can't have radiation therapy after surgery.
This trial tests if a daily pill called Rezvilutamide can prevent prostate cancer from returning in men who had their prostate removed and are at high risk of recurrence. It is for men who cannot or choose not to have radiation therapy.
This Phase 2 study tests rezvilutamide in men whose prostate-specific antigen (PSA) starts rising again after the prostate has been removed. It aims to see whether this treatment can help prevent or slow cancer spread after surgery, especially in men without signs of spread on scans.
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Preoperative Evaluation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.